Advanced search

Found 3 essays matching the above criteria.

  1. 1. Classification of imbalanced disparate medical data using ontology

    University essay from KTH/Skolan för elektroteknik och datavetenskap (EECS)

    Author : Ludvig Karlsson; Gustav Wilhelm Kopp Sundin; [2023]
    Keywords : Ontology; machine learning; random forest; imbalanced data; oncology; digital transformation;

    Abstract : Through the digitization of healthcare, large volumes of data are generated and stored in healthcare operations. Today, a multitude of platforms and digital infrastructures are used for storage and management of data. The systems lack a common ontology which limits the interoperability between datasets. READ MORE

  2. 2. Censoring Bias in Oncology Clinical Trials

    University essay from Lunds universitet/Matematisk statistik

    Author : Andrea Mattsson; [2020]
    Keywords : survival analysis; censoring; progression-free survival; Cox proportional hazards model; oncology clinical trial; HER2CLIMB; Mathematics and Statistics;

    Abstract : Time to disease progression or death (PFS) is of main interest in oncology clinical trials. The data is commonly analyzed using a Cox model. Early discontinuation gives uncertainty in the estimated hazard ratio (HR). Censoring is generally used to handle discontinuations. READ MORE

  3. 3. On the Valuation of ‘Big Pharma’s’ Research Pipelines

    University essay from Institutionen för ekonomisk och industriell utveckling

    Author : Martin Löfqvist; [2009]
    Keywords : Big Pharma; Clinical Trials; Econometrics; Valuation; Research and Development;

    Abstract : Background: Tougher demands from regulators on drugs efficiency and safety,governmental cost cutting and more complex areas of research, has led to that the importance of the pharmaceutical industry’s research pipelines are increasing. Even though the capital markets views on the pharmaceutical industry and its valuation is changing, the authors is not aware of any prior research that has been conducted on the topic of how the market reacts to clinical trial results or how security analysts valuates product pipelines. READ MORE